NVS Novartis AG

+0.38  (+0%)
Previous Close 82.01
Open 82.68
Price To Book 4.05
Market Cap 191377794471
Shares 2,322,827,946
Volume 2,152,554
Short Ratio 0.84
Av. Daily Volume 2,744,767

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Head-to-head trial versus proposed biosimilar adalimumab initiated. Expected completion 2022.
Cosentyx (secukinumab) - SURPASS
Ankylosing spondylitis (AS)
Approval announced April 30, 2018.
Tafinlar (dabrafenib) and Mekinist (trametinib)
Melanoma with BRAF V600E or V600K mutations
Phase 3 trial to be completed 2H 2020.
Metastatic castration-resistant prostate cancer (mCRPC)
Approval announced May 11, 2018.
Multiple Sclerosis (MS)
Phase 1 data at AAN May 5, 2019 noted motor function gains.
Zolgensma AVXS-101 STRONG
Spinal muscular atrophy (SMA) Type 2
FDA Approval announced June 22, 2017.
Tafinlar (dabrafenib) and Mekinist (trametinib)
Non-small cell lung cancer (NSCLC) with BRAF V600E mutation
Approval announced May 1, 2018.
Kymriah (CTL019 )- JULIET
Cancer - Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 3 updated data at ASCO June 4, 2017.
Ribociclib + Letrozole - MONALEESA-2
Breast cancer
CRL issued May 2, 2018.
Biosimilar rituximab
Various blood cancers, rheumatoid arthritis.
Priority review granted February 22, 2017. Approval announced May 26, 2017.
First-line use in patients with ALK+ metastatic NSCLC
Phase 3 data due by the end of 2019.
Ruxolitinib - REACH 3
Steroid-refractory chronic GVHD (Graft versus host disease)
Phase 3 data due 2H 2019.
Ruxolitinib - REACH 2
Steroid-refractory acute GVHD (Graft versus host disease)
CRL announced October 18, 2018.
ACZ885 (canakinumab)
CV risk reduction
Phase 3 data released March 22, 2017 - primary endpoints not met.
Acute heart failure
PDUFA date under priority review estimated October 15, 2019 using six-month timeline. Exact date not provided by company.
RTH258 (brolucizumab)
Neovascular AMD
Phase 3 trial to be completed 3Q 2019.
Phase 3 data due 2H 2019.
QAW039 (fevipiprant)
Phase 3 trial met primary endpoint - November 8, 2017.
Breast cancer - (pre-menopausal)
Phase 3 data due 2H 2019.
OMB157 (ofatumumab)
Relapsing multiple sclerosis
Phase 3 data presented at ASCO 2018 - PFS 20.5 months v 12.8 months
Kisqali plus fulvestrant: MONALEESA-3
Breast cancer - (post-menopausal)
Phase 3 data due 2H 2019.
Entresto - PARAGON
HF-pEF (heart failure with preserved ejection fraction)
Phase 3 trial completion due 2H 2020.
Entresto - PARADISE
AMI (acute myocardial infarction)
Approval announced early - August 30, 2017.
Kymriah (CTL019)
Relapsed/Refractory B-Cell Acute lymphoblastic leukemia
Phase 3 trial to be completed 2Q 2019.
AIN457 (Cosentyx)
Psoriatic arthritis
Approval announced May 17, 2018.
Phase 3 ongoing. Expected completion 2024.
CNP 520
Alzheimer’s Disease
Priority review granted November 14, 2016. Approval announced April 28, 2017.
Rydapt (Midostaurin - PKC412)
Acute myeloid leukemia (AML)
Priority review granted November 1, 2016. Approval announced March 13, 2017.
HR+/HER2- advanced breast cancer
FDA approval announced October 31, 2018.
Rheumatoid Arthritis
Approved January 26, 2018. Acquired from Advanced Accelerator Applications (NASDAQ: AAAP).
Inoperable progressive midgut NETs
PDUFA date under priority review May 2019. Exact date not released.
Zolgensma AVXS-101
Spinal muscular atrophy (SMA) Type 1
PDUFA date under priority review extended by three months to May 24, 2019.
Graft versus host disease
Phase 3 data May 5, 2019 noted 11/22 patients who could sit without support for at least 30 seconds. To be completed in 2021.
Zolgensma AVXS-101 STR1VE EU
Spinal muscular atrophy (SMA) Type 1
Phase 2 interim analysis 1H 2018.
Non-alcoholic steatohepatitis (NASH)
Phase 2 released October 19, 2018. ORR 72% in treatment-naive patients, 39% in previously treated patients. Presentation at ASCO June 3, 2019, 9:12am CT.
Non-small cell lung cancer
Program discontinued - noted July 18, 2018.
Phase 3 trial met primary endpoint - August 23, 2018. PFS 11 months v 5.7 months for fulvestrant alone.
BYL719 + fulvestrant
HR + Metastatic breast cancer (MBC)
FDA approval announced February 8, 2018.
Phase 3 data May 5, 2019 noted all patients (18/18) were alive and event-free. Completion 2021.
Zolgensma AVXS-101 SPRINT
Pre-symptomatic patients with spinal muscular atrophy (SMA) Types 1, 2 and 3
sNDA approval announced November 16, 2018.
Promacta (eltrombopag)
Severe aplastic anemia (SAA)
FDA approval announced March 26, 2019.
Mayzent (siponimod/BAF312)
Secondary progressive multiple sclerosis
Phase 3 data due 2H 2019.
BRAFV600 mutant metastatic melanoma
Phase 3 data noted 46% reduction in serious clinical outcomes endpoint.
Entresto - PIONEER
Heart failure
Regulatory filing due 1H 2019.
Sickle cell disease
Phase 3 trial completed 1Q 2019.
Entresto - PARALLEL-HF
Heart failure
Phase 3 data due 2H 2019.
Cosentyx (secukinumab) - PREVENT
Non-radiographic axial spondyloarthritis
FDA Approval announced February 13, 2019.
BLA filing resubmission announced April 3, 2019 in response to CRL issued in 2017. Estimated PDUFA date February 3, 2020.
Biosimilar pegfilgrastim
Pegfilgrastim biosimilar
Phase 3 trial to be completed 2022.
Heart failure
Phase 3 trial to be completed 2021.
Entresto - Panorama
Heart failure

Latest News

  1. Cramer Remix: The cannabis stocks I'm eyeing
  2. Fix 'distortions' in health care system ahead of slate of drug launches: Novartis CEO
  3. Novartis CEO calls for fixing 'distortions' in health care system ahead of slate of drug launches
  4. Novartis CEO calls for fixing 'distortions' in health care system ahead of slate of drug launches
  5. These 3 Major Drug Manufacturers Are Strong Performers
  6. Novartis CEO says cannabis isn't a focus despite Tilray partnership
  7. Novartis CEO on single-payer health care: It is not the right move for America
  8. Adverum Up as FDA Lifts Hold on Cohort of Wet AMD Study
  9. Primary Drivers of the Chinese Economy
  10. 3 Ways to Buy Into the Marijuana Boom Without the Risk
  11. Ligand Grants Preclinical Candidate Rights to UK-based Firm
  12. Don’t Let the Great Q1 Numbers Fool You into Buying Tilray Stock
  13. Commentary: Novartis CEO says gene therapies promise to upend US health system, pricing structure
  14. Commentary: Novartis CEO: Gene therapy offers hope of cures in one treatment, but US needs new pricing and payment model
  15. GSK and Novartis liniment marketing misled Australian consumers - court
  16. Tilray Stock Is Red-Hot, But It’s Fundamentally Flawed
  17. Three Conservative Ways to Play Cannabis
  18. Teva Hits Fibonacci Support on Concerns Over Lawsuit
  19. The Zacks Analyst Blog Highlights: Teva, Mylan, Novartis and Pfizer
  20. Novartis gets approval to sell Kymriah in Japan for $306,000